Table 2.
Note.—Unless otherwise noted, data are numbers of subjects, with percentages in parentheses. Thirty-eight (as opposed to 39) false-positive controls were included because there was one case for which no matched control could be identified.
Numbers in parentheses are age ranges.
Raloxifene (Evista) is manufactured by Eli Lilly and Company (Indianapolis, Ind); tamoxifen (Nolvadex) is manufactured by various companies.
Risk factor for breast cancer determined at MR imaging screening. LCIS = lobular carcinoma in situ.
Remaining uninvolved and nontreated breast was examined at screening MR imaging.
All lumpectomies were performed more than 5 years before the high-risk breast MR imaging screening examination.